Two congressmen are calling on the federal Justice Department to investigate drug companies—including Indianapolis-based Eli Lilly—for possible price fixing of insulin products.
In a letter, Vermont senator Bernie Sanders and Maryland representative Elijah Cummings criticize three insulin manufacturers for skyrocketing insulin prices. The letter alleges the prices have been raised in tandem with each other, indicating potential collusion.
“Three drugmakers have continuously raised prices on this life-saving medication,” the letter reads. “In numerous instances, price increases have reportedly mirrored one another precisely.”
Representatives from Eli Lilly declined an interview, but in a statement roundly denied the claims of the letter. “We strongly disagree with the accusation,” the statement says. “The insulin market in the U.S. is highly competitive.” Lilly points out even though the list price for its insulin has risen, the net realized price hasn’t increased since 2009.
Pharmaco-economist and instructor of medicine at Brigham and Women’s Hospital Jing Luo, who researches the insulin market, is skeptical of Lilly’s claims. However, he says just because prices are similar doesn’t mean companies are collaborating.
“Do manufacturers know prices for their competitors? Yes,” says Luo. “So if they see their competitors’ price go up, they could theoretically increase their own price to match.”
Full Content: Indiana Public Media
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
China Summons Delivery Giants Over Unfair Competition Concerns
May 13, 2025 by
CPI
Judge Orders Sanctions Against Missouri for Noncompliance in Price-Fixing Probe
May 13, 2025 by
CPI
Confusion Reigns In AI Policy In US and Europe
May 13, 2025 by
CPI
EU Clears ADNOC’s $16.3 Billion Acquisition of Covestro
May 13, 2025 by
CPI
Spanish Antitrust Chief Says BBVA-Sabadell Merger Won’t Stifle Competition
May 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece